In 125 eligible patients with oligometastatic breast cancer on first-line systemic therapy, adding metastasis-directed ablation (mostly SBRT) did not improve PFS (median 19.5 vs 23.0 months; HR 0.92) or overall survival; the trial did not proceed to phase III.
RCTn = 129
Chmura et al. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer